Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination drug consisting of oximeromide (羟利溴铵) and levobupivacaine (左布比卡因). Oximeromide is a potent opioid analgesic, while levobupivacaine is an amide-type local anesthetic. The combination aims to provide both strong analgesia and local anesthesia for surgical procedures or acute pain management. Levobupivacaine works by blocking voltage-gated sodium channels in neuronal membranes, inhibiting nerve impulse conduction and thus producing local anesthesia. Oximeromide acts primarily as a mu-opioid receptor agonist, providing systemic analgesia through central nervous system mechanisms. This combination may be used for infiltration anesthesia or nerve block during surgery or for acute pain control[1][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on oximeromide + levobupivacaine.